CN1612751A - 包括施用抗IgE抗体和抗过敏化合物、用于过敏性疾病的组合治疗 - Google Patents

包括施用抗IgE抗体和抗过敏化合物、用于过敏性疾病的组合治疗 Download PDF

Info

Publication number
CN1612751A
CN1612751A CNA03802053XA CN03802053A CN1612751A CN 1612751 A CN1612751 A CN 1612751A CN A03802053X A CNA03802053X A CN A03802053XA CN 03802053 A CN03802053 A CN 03802053A CN 1612751 A CN1612751 A CN 1612751A
Authority
CN
China
Prior art keywords
composition according
allergic
omalizumab
allergic diseases
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA03802053XA
Other languages
English (en)
Chinese (zh)
Inventor
C·E·欧文
H·G·福克斯
C·沃克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1612751A publication Critical patent/CN1612751A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA03802053XA 2002-01-09 2003-01-09 包括施用抗IgE抗体和抗过敏化合物、用于过敏性疾病的组合治疗 Pending CN1612751A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0200429.9A GB0200429D0 (en) 2002-01-09 2002-01-09 Organic compounds
GB0200429.9 2002-01-09

Publications (1)

Publication Number Publication Date
CN1612751A true CN1612751A (zh) 2005-05-04

Family

ID=9928810

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA03802053XA Pending CN1612751A (zh) 2002-01-09 2003-01-09 包括施用抗IgE抗体和抗过敏化合物、用于过敏性疾病的组合治疗

Country Status (9)

Country Link
US (2) US20050042215A1 (https=)
EP (1) EP1465662A1 (https=)
JP (1) JP2005514414A (https=)
CN (1) CN1612751A (https=)
AU (1) AU2003210153A1 (https=)
BR (1) BR0306732A (https=)
CA (1) CA2472151A1 (https=)
GB (1) GB0200429D0 (https=)
WO (1) WO2003057249A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112203724A (zh) * 2018-03-26 2021-01-08 诺华股份有限公司 使用利格珠单抗治疗慢性自发性荨麻疹的方法
CN114504644A (zh) * 2021-12-24 2022-05-17 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512946A (ja) * 2001-05-09 2005-05-12 ノバルティス アクチエンゲゼルシャフト 選択的免疫調節法
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
CA2539324A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
WO2005030331A1 (en) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
JP4974903B2 (ja) * 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
AU2008215926B2 (en) * 2007-02-15 2012-07-19 Astrazeneca Ab Binding members for IgE molecules
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
BR112020006339A2 (pt) * 2017-11-07 2020-11-03 Hubit Genomix, Inc. método para prevenção primária de distúrbios alérgicos durante a infância através de imunossupressão específica da classe ige

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
WO2000016804A1 (en) * 1998-09-18 2000-03-30 Dynavax Technologies Corporation METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN
GB0012383D0 (en) * 2000-05-22 2000-07-12 Novartis Ag Organic compounds

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112203724A (zh) * 2018-03-26 2021-01-08 诺华股份有限公司 使用利格珠单抗治疗慢性自发性荨麻疹的方法
CN114504644A (zh) * 2021-12-24 2022-05-17 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用
CN114504644B (zh) * 2021-12-24 2024-02-13 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用

Also Published As

Publication number Publication date
CA2472151A1 (en) 2003-07-17
US20050042215A1 (en) 2005-02-24
JP2005514414A (ja) 2005-05-19
WO2003057249A1 (en) 2003-07-17
AU2003210153A1 (en) 2003-07-24
BR0306732A (pt) 2004-12-28
GB0200429D0 (en) 2002-02-27
EP1465662A1 (en) 2004-10-13
US20060240000A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
Lane et al. Treatment of recalcitrant atopic dermatitis with omalizumab
CN1612751A (zh) 包括施用抗IgE抗体和抗过敏化合物、用于过敏性疾病的组合治疗
US20080206237A1 (en) Synergistic Combination Of Xolair/Omalizumab/E25 With Immunosuppressive Agent
CN1829532A (zh) 肌肉抑制素（gdf8）抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途
EP2969010B1 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
US20230126987A1 (en) Methods for treating cytokine storm syndrome and related diseases
WO2021255621A1 (en) Treatment of food allergy using anti-ige antibodies
WO2004067006A1 (en) Combination of a pde iv inhibitor and a tnf-alpha antagonist
KR20240116810A (ko) 항-ige 항체를 사용한 알레르기 반응의 치료
TW201204360A (en) Treatment of multiple sclerosis with MASITINIB
EP3520803A1 (en) Novel uses
EP4531856B1 (en) Bruton's kinase inhibitors for the treatment of a sudden allergic reaction
WO2021173740A1 (en) Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase
KR100756974B1 (ko) 알레르기 질환 및 만성염증성 질환의 치료를 위한 약학적 조성물 및 키트
AU2021293980A1 (en) Treatment of food allergy using anti-IgE antibodies
RU2854872C1 (ru) Лечение аллергии на пищевые продукты с применением антител к ige
WO2006098607A1 (en) Histamine-containing composition for the treatment of allergic diseases
US20100130457A1 (en) Phenothiazine Derivatives for Treatment of Asthma
WO2023202439A1 (zh) 二萜化合物衍生物或其盐在制备防治特应性皮炎的药物中的应用
WO2024027790A1 (zh) 吡咯并嘧啶化合物治疗急性移植物抗宿主病的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication